Pharmatek To Make ANX-201 for Adventrx Trials

Adventrx Pharmaceuticals, Inc. has entered into an agreement with Pharmatek Laboratories for the manufacture of ANX-201 (Thiovir) capsules for clinical studies.

“Pharmatek is an experienced contract manufacturer and we are confident in their ability to produce reliable cGMP material for our clinical trials,” said Michele Yelmene, vice president of regulatory affairs. “The drug supply they generate under this contract is expected to provide the company with inventory for our Phase 1/2 study in HIV, which we anticipate initiating later this year.”

Adventrx plans to file an IND with the FDA in 2Q2007, pending appropriate clearances, and to initiate a Phase 1/2 trial of ANX-201 as a component of multi-drug therapy for the treatment of HIV, in 3Q2007.